Photodynamic Inactivation of Microbial Pathogens
248,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in über 4 Wochen
payback
124 °P sammeln
  • Gebundenes Buch

This book is the first to comprehensively cover this interesting and rapidly spreading topic, namely the use of visible light and photosensitising agents for controlling the population of microbial pathogens. Edited by two pioneers in the application of this technique for addressing both medical and environmental issues, and bringing together the foremost practitioners internationally in this field, this up-to-date account will address basic/mechanistic aspects followed by an exhaustive coverage of the current medical applications and environmentally friendly approaches. The book will be an…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
This book is the first to comprehensively cover this interesting and rapidly spreading topic, namely the use of visible light and photosensitising agents for controlling the population of microbial pathogens. Edited by two pioneers in the application of this technique for addressing both medical and environmental issues, and bringing together the foremost practitioners internationally in this field, this up-to-date account will address basic/mechanistic aspects followed by an exhaustive coverage of the current medical applications and environmentally friendly approaches. The book will be an indispensable resource for students and professionals working in fields relating to photochemistry, environmental science and medical applications for photodynamic therapy.
Autorenporträt
Dr Michael R. Hamblin is a Principal Investigator at the Wellman Center for Photomedicine at Massachusetts General Hospital and an Associate Professor of Dermatology at Harvard Medical School. He received his PhD in synthetic organic chemistry from Trent University in England. His interests lie in photodynamic therapy for infections, cancer, and heart disease and also in low-level light therapy for wound healing, arthritis, traumatic brain injury and hair regrowth. His research program is supported by NIH, CDMRP and CIMIT among others. He has published over 125 peer-reviewed articles, over 120 conference proceedings, book chapters and international abstracts, and holds 8 patents.